Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Giulia Mentrast"'
Autor:
Giulia Mentrasti, Luca Cantini, Patrizia Vici, Nicola D'Ostilio, Nicla La Verde, Rita Chiari, Vittorio Paolucci, Sonia Crocetti, Chiara De Filippis, Federica Pecci, Francesca Sofia Di Lisa, Donatella Traisci, Maria Silvia Cona, Linda Nicolardi, Laura Pizzuti, Simona Gildetti, Simone Oldani, Arianna Della Mora, Marco Luigi Bruno Rocchi, Rossana Berardi
Publikováno v:
Breast, Vol 65, Iss , Pp 164-171 (2022)
Purpose: Breast cancer (BC) patients’ (pts) management was affected by a global reorganization after Coronavirus disease 2019 (COVID-19). Our multicenter study aimed to assess the impact of COVID-19 on access to diagnosis, staging and treatment for
Externí odkaz:
https://doaj.org/article/5a1c9c5ec8c048d8a0f712de03031afa
Autor:
Sara Fancelli, Enrico Caliman, Francesca Mazzoni, Luca Paglialunga, Marta Rita Gatta Michelet, Daniele Lavacchi, Rossana Berardi, Giulia Mentrasti, Giulio Metro, Ilaria Birocchi, Angelo Delmonte, Ilaria Priano, Camilla Eva Comin, Francesca Castiglione, Caterina Bartoli, Luca Voltolini, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundKRAS is commonly mutated in non-small cell lung cancer (NSCLC); however, the prognostic and predictive impact of each G12 substitution has not been fully elucidated. The approval of specific G12C inhibitors has modified the idea of KRAS “
Externí odkaz:
https://doaj.org/article/a435761aa6044f71a9054275e098102e
Autor:
Alessandro Bittoni, Riccardo Giampieri, Federica Pecci, Giada Pinterpe, Alessandra Mandolesi, Michela Del Prete, Antonio Zizzi, Sonia Crocetti, Carolina Liguori, Giulia Mentrasti, Luca Cantini, Chiara Pellei, Renato Bisonni, Marina Scarpelli, Rossana Berardi
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3525-3536 (2021)
Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC
Externí odkaz:
https://doaj.org/article/eb8e120972bf489ea1cff21db2076297
Autor:
Riccardo Giampieri, Elena Maccaroni, Valeria Sotte, Maria G. Baleani, Tania Meletani, Enrica Giglio, Federica Pecci, Alessandro Bittoni, Andrea Lanese, Luca Cantini, Giulia Mentrasti, Alessandra Lucarelli, Rossana Berardi
Publikováno v:
Oncology and Therapy, Vol 8, Iss 1, Pp 161-169 (2019)
Abstract Neurotoxicity is one of the most common side effects of oxaliplatin-based therapy. Most patients who receive at least 3–4 months of treatment suffer from peripheral sensory neurotoxicity (PSN), characterised by the loss or impairment of ta
Externí odkaz:
https://doaj.org/article/e754b4f6a03f4a02960ee3447a8bc5e7
Autor:
Francesco Sclafani, Ian Chau, David Cunningham, Jens C. Hahne, George Vlachogiannis, Zakaria Eltahir, Andrea Lampis, Chiara Braconi, Eleftheria Kalaitzaki, David Gonzalez De Castro, Andrew Wotherspoon, Jaume Capdevila, Bengt Glimelius, Noelia Tarazona, Ruwaida Begum, Hazel Lote, Sanna Hulkki Wilson, Giulia Mentrasti, Gina Brown, Diana Tait, Jacqueline Oates, Nicola Valeri
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018)
Abstract There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients
Externí odkaz:
https://doaj.org/article/2003b11877bd4935942baabe372bee21
Autor:
Mahnaz Darvish-Damavandi, Giulia Mentrast, Sarah Barton, Ian Chau, David Watkins, Sheela Rao, Khurum Khan, Naureen Starling, George Vlachogianis, David Cunningham, Nicola Valeri, Andrea Lampis, Ruwaida Begum, Francesco Trevisani, Chiara Braconi, Jens C. Hahne, Nasir Khan, Clare Peckitt, Annette Bryant
Publikováno v:
Cancer Research. 75:3589-3589
Background: AE-mABs (cetuximab and/or panitumumab) have been approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Indeed, previous studies have identified mutations (MTs)/amplifications in RAS/RAF/MEK k